Because the tumor onset was significantly delayed in Chk1 heterozygous Eμ-MYC mice and B cells showed a dose-dependent response to CHK1i ex vivo, we propose that there is a potential window of opportunity to treat CHK1i sensitive tumors without inducing severe side-effects that associate with complete loss of CHK1 activity. Here, MYC is linked to neoplasm.